These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 35507498)

  • 21. Pembrolizumab in the preoperative setting of triple-negative breast cancer: safety and efficacy.
    Barroso-Sousa R; Tolaney SM
    Expert Rev Anticancer Ther; 2020 Nov; 20(11):923-930. PubMed ID: 32930616
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pembrolizumab shows potential in breast cancer.
    Cancer Discov; 2015 Feb; 5(2):100-1. PubMed ID: 25656879
    [No Abstract]   [Full Text] [Related]  

  • 23. Efficacy and safety of pembrolizumab based therapies in triple-negative breast cancer: A systematic review of clinical trials.
    Ali MA; Aiman W; Shah SS; Hussain M; Kashyap R
    Crit Rev Oncol Hematol; 2021 Jan; 157():103197. PubMed ID: 33309890
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pembrolizumab for Early Triple-Negative Breast Cancer. Reply.
    Schmid P; Dent R; O'Shaughnessy J
    N Engl J Med; 2020 Jun; 382(26):e108. PubMed ID: 32579835
    [No Abstract]   [Full Text] [Related]  

  • 25. Pembrolizumab in Triple-Negative Breast Cancer.
    Sun R; Wei LJ
    N Engl J Med; 2022 Oct; 387(15):1435. PubMed ID: 36239656
    [No Abstract]   [Full Text] [Related]  

  • 26. Pembrolizumab in Triple-Negative Breast Cancer.
    Altundag K
    N Engl J Med; 2022 Oct; 387(15):1435-1436. PubMed ID: 36239657
    [No Abstract]   [Full Text] [Related]  

  • 27. Pembrolizumab Improves Outcomes in Early-Stage and Locally Advanced or Metastatic Triple-Negative Breast Cancer.
    Jacobson A
    Oncologist; 2022 Mar; 27(Suppl 1):S17-S18. PubMed ID: 35348777
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pembrolizumab monotherapy in metastatic triple-negative breast cancer.
    Amir E; Cescon DW
    Lancet Oncol; 2021 Apr; 22(4):415-417. PubMed ID: 33676605
    [No Abstract]   [Full Text] [Related]  

  • 29. [Not Available].
    Gonçalves A
    Bull Cancer; 2016 Jun; 103(6 Suppl 1):S76-89. PubMed ID: 27494978
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inflammatory breast cancer with excellent response to pembrolizumab-chemotherapy combination: A case report.
    Kharel Z; Nemer OP; Xi W; Upadhayaya B; Falkson CI; O'Regan RM; Dhakal A
    Breast Dis; 2022; 41(1):255-260. PubMed ID: 35599460
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Pembrolizumab plus chemotherapy combination - first line in PD-L1 positive (CPS≥10) metastatic and advanced triple-negative breast cancer].
    Loison R; Loirat D
    Bull Cancer; 2022 Apr; 109(4):387-389. PubMed ID: 35256159
    [No Abstract]   [Full Text] [Related]  

  • 32. Phase II open-label study of bevacizumab combined with neoadjuvant anthracycline and taxane therapy for locally advanced breast cancer.
    Clavarezza M; Turazza M; Aitini E; Saracchini S; Garrone O; Durando A; De Placido S; Bisagni G; Levaggi A; Bighin C; Restuccia E; Scalamogna R; Galli A; Del Mastro L
    Breast; 2013 Aug; 22(4):470-5. PubMed ID: 23642526
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer.
    Cortes J; Rugo HS; Cescon DW; Im SA; Yusof MM; Gallardo C; Lipatov O; Barrios CH; Perez-Garcia J; Iwata H; Masuda N; Torregroza Otero M; Gokmen E; Loi S; Guo Z; Zhou X; Karantza V; Pan W; Schmid P;
    N Engl J Med; 2022 Jul; 387(3):217-226. PubMed ID: 35857659
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update.
    Korde LA; Somerfield MR; Hershman DL;
    J Clin Oncol; 2022 May; 40(15):1696-1698. PubMed ID: 35417251
    [No Abstract]   [Full Text] [Related]  

  • 35. Excellent Response to Atezolizumab After Clinically Defined Hyperprogression Upon Previous Treatment With Pembrolizumab in Metastatic Triple-Negative Breast Cancer: A Case Report and Review of the Literature.
    Feng D; Guan Y; Liu M; He S; Zhao W; Yin B; Liang J; Li Y; Wang J
    Front Immunol; 2021; 12():608292. PubMed ID: 34135884
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Atezolizumab and pembrolizumab in triple-negative breast cancer: a meta-analysis.
    Latif F; Bint Abdul Jabbar H; Malik H; Sadaf H; Sarfraz A; Sarfraz Z; Cherrez-Ojeda I
    Expert Rev Anticancer Ther; 2022 Feb; 22(2):229-235. PubMed ID: 34949142
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An ADC for Triple-Negative Breast Cancer.
    Cancer Discov; 2016 Jan; 6(1):OF8. PubMed ID: 26577300
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting immune pathways in breast cancer: review of the prognostic utility of TILs in early stage triple negative breast cancer (TNBC).
    Blackley EF; Loi S
    Breast; 2019 Nov; 48 Suppl 1():S44-S48. PubMed ID: 31839159
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunotherapy addition to neoadjuvant chemotherapy for early triple negative breast cancer: A systematic review and meta-analysis of randomized clinical trials.
    Tarantino P; Gandini S; Trapani D; Criscitiello C; Curigliano G
    Crit Rev Oncol Hematol; 2021 Mar; 159():103223. PubMed ID: 33482345
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of patients with early-stage triple-negative breast cancer following pembrolizumab-based neoadjuvant therapy: What are the evidences?
    Bonadio RC; Tarantino P; Testa L; Punie K; Pernas S; Barrios C; Curigliano G; Tolaney SM; Barroso-Sousa R
    Cancer Treat Rev; 2022 Nov; 110():102459. PubMed ID: 35998514
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.